{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T20:20:30Z","timestamp":1790194830668,"version":"4.1.0"},"reference-count":240,"publisher":"Wiley","issue":"35","license":[{"start":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T00:00:00Z","timestamp":1780963200000},"content-version":"vor","delay-in-days":8,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/doi.wiley.com\/10.1002\/tdm_license_1.1"}],"content-domain":{"domain":["advanced.onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["Advanced Science"],"published-print":{"date-parts":[[2026,6]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:p>Cancer immunotherapy has fundamentally transformed the management of solid tumors, ranging from immune checkpoint blockade to a broader spectrum of immune\u2010modulating strategies. While inhibitors of CTLA\u20104 and the PD\u20101\/PD\u2010L1 axis remain central to clinical practice, heterogeneous clinical responses, immune\u2010related toxicities, and different resistance mechanisms underscore the need for next\u2010generation approaches. This review integrates recent advances in cancer immunotherapy for solid tumors, with an emphasis on emerging biological concepts and therapeutic platforms that extend beyond classical checkpoint inhibition. We discuss novel immune checkpoints, biomarker\u2010driven approvals, and the expanding role of immunotherapy in different disease settings. Antibody\u2010based platforms are highlighted as strategies that integrate direct tumor targeting with immune activation, which have reshaped standards of care in several malignancies. We further review advances in adoptive cellular therapies as well as next\u2010generation cytokine therapies and cancer vaccines aimed at enhancing tumor\u2010specific immune responses while mitigating systemic toxicity. Finally, we address key unresolved challenges, including mechanisms of resistance, optimization of sequencing and dosing strategies, and clinical trial design considerations. Together, these developments reflect a rapidly evolving field focused on broadening efficacy, improving safety, and personalizing treatment in solid tumors.<\/jats:p>","DOI":"10.1002\/advs.76020","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T10:00:29Z","timestamp":1780999229000},"update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Advances in Cancer Immunotherapy for Solid Tumors"],"prefix":"10.1002","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1494-6510","authenticated-orcid":false,"given":"Shira","family":"Gabizon\u2010Peretz","sequence":"first","affiliation":[{"name":"Medical Oncology Yale University  New Haven Connecticut USA"},{"name":"Davidoff Cancer Center, Petah Tikva, Faculty of Medicine Tel\u2010Aviv University  Tel Aviv\u2010Yafo Israel"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4932-9873","authenticated-orcid":false,"given":"Harriet M.","family":"Kluger","sequence":"additional","affiliation":[{"name":"Medical Oncology Yale University  New Haven Connecticut USA"},{"name":"Smilow Cancer Hospital at Yale New Haven  New Haven Connecticut USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2026,6,9]]},"reference":[{"key":"e_1_2_11_2_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.1995.13.3.688"},{"key":"e_1_2_11_3_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1504030"},{"key":"e_1_2_11_4_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.02229"},{"key":"e_1_2_11_5_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1003466"},{"key":"e_1_2_11_6_1","first-page":"2517","volume-title":"Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma","author":"Robert C.","year":"2011"},{"key":"e_1_2_11_7_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-024-01826-z"},{"key":"e_1_2_11_8_1","volume-title":"Figures for Advances in Cancer Immunotherapy for Solid Tumors","author":"BioRender Ci","year":"2026"},{"key":"e_1_2_11_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.intimp.2024.113365"},{"key":"e_1_2_11_10_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms22105282"},{"key":"e_1_2_11_11_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-14-0150"},{"key":"e_1_2_11_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01238-7"},{"key":"e_1_2_11_13_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41590-022-01176-4"},{"key":"e_1_2_11_14_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2003-01-0273"},{"key":"e_1_2_11_15_1","doi-asserted-by":"publisher","DOI":"10.1111\/imr.12519"},{"key":"e_1_2_11_16_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2109970"},{"key":"e_1_2_11_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115547"},{"key":"e_1_2_11_18_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers12082329"},{"key":"e_1_2_11_19_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12885-025-14546-6"},{"key":"e_1_2_11_20_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2021.39.15_suppl.9516"},{"key":"e_1_2_11_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.02072"},{"key":"e_1_2_11_22_1","doi-asserted-by":"publisher","DOI":"10.1093\/neuonc\/noaf201.0902"},{"key":"e_1_2_11_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2023.41.16_suppl.TPS9605"},{"key":"e_1_2_11_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-022-05368-8"},{"key":"e_1_2_11_25_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00494"},{"key":"e_1_2_11_26_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-024-02965-0"},{"key":"e_1_2_11_27_1","article-title":"Clinical Activity of fianlimab (REGN3767) plus Cemiplimab in Advanced melanoma","volume":"39","author":"Hamid O.","year":"2021","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_28_1","article-title":"A Phase 3 Trial of Fixed\u2010Dose Combinations of Fianlimab (anti\u2013LAG\u20103) plus cemiplimab (anti\u2013PD\u20101) in Advanced melanoma","volume":"42","author":"Hamid O.","year":"2024","journal-title":"J Clin Oncol"},{"key":"e_1_2_11_29_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-05-2728"},{"key":"e_1_2_11_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.08.2274"},{"key":"e_1_2_11_31_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02593-0"},{"key":"e_1_2_11_32_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21844"},{"key":"e_1_2_11_33_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13030467"},{"key":"e_1_2_11_34_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms26094394"},{"key":"e_1_2_11_35_1","doi-asserted-by":"publisher","DOI":"10.1126\/science.aan6733"},{"key":"e_1_2_11_36_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.18.01042"},{"key":"e_1_2_11_37_1","doi-asserted-by":"publisher","DOI":"10.1158\/2326-6066.CIR-20-0983"},{"key":"e_1_2_11_38_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2021.09.016"},{"key":"e_1_2_11_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz205"},{"key":"e_1_2_11_40_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.iotech.2019.11.003"},{"key":"e_1_2_11_41_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyab064"},{"key":"e_1_2_11_42_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.lungcan.2024.107506"},{"key":"e_1_2_11_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(17)30516-8"},{"key":"e_1_2_11_44_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1369189"},{"key":"e_1_2_11_45_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0263585"},{"key":"e_1_2_11_46_1","doi-asserted-by":"publisher","DOI":"10.1200\/PO.21.00267"},{"key":"e_1_2_11_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30445-9"},{"key":"e_1_2_11_48_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.02105"},{"key":"e_1_2_11_49_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-024-00894-y"},{"key":"e_1_2_11_50_1","first-page":"2207","volume-title":"Pembrolizumab in Microsatellite\u2010Instability\u2013High Advanced Colorectal Cancer","author":"Andr\u00e9 T.","year":"2020"},{"key":"e_1_2_11_51_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.11.012"},{"key":"e_1_2_11_52_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)02848-4"},{"key":"e_1_2_11_53_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2023.41165"},{"key":"e_1_2_11_54_1","first-page":"2145","volume-title":"Dostarlimab for Primary Advanced or Recurrent Endometrial Cancer","author":"Mirza M. R.","year":"2023"},{"key":"e_1_2_11_55_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA3512"},{"key":"e_1_2_11_56_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.3_suppl.TPS240"},{"key":"e_1_2_11_57_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2404512"},{"key":"e_1_2_11_58_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-01851-x"},{"key":"e_1_2_11_59_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2021-002485"},{"key":"e_1_2_11_60_1","first-page":"1973","volume-title":"Neoadjuvant Nivolumab plus Chemotherapy in Resectable Lung Cancer","author":"Forde P. M.","year":"2022"},{"key":"e_1_2_11_61_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2021.11.030"},{"key":"e_1_2_11_62_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.02.005"},{"key":"e_1_2_11_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2100070"},{"key":"e_1_2_11_64_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00105009"},{"key":"e_1_2_11_65_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1809064"},{"key":"e_1_2_11_66_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(19)32222-6"},{"key":"e_1_2_11_67_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1712126"},{"key":"e_1_2_11_68_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4505"},{"key":"e_1_2_11_69_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.01569"},{"key":"e_1_2_11_70_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.22.01763"},{"key":"e_1_2_11_71_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.aaa4691"},{"key":"e_1_2_11_72_1","doi-asserted-by":"publisher","DOI":"10.1111\/pcmr.12383"},{"key":"e_1_2_11_73_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMc1302338"},{"key":"e_1_2_11_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(20)30934-X"},{"key":"e_1_2_11_75_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00687-8"},{"key":"e_1_2_11_76_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-023-00372-8"},{"key":"e_1_2_11_77_1","first-page":"1823","volume-title":"Pembrolizumab versus Chemotherapy for PD\u2010L1\u2013Positive Non\u2013Small\u2010Cell Lung Cancer","author":"Reck M.","year":"2016"},{"key":"e_1_2_11_78_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00329-7"},{"key":"e_1_2_11_79_1","first-page":"1328","volume-title":"Atezolizumab for First\u2010Line Treatment of PD\u2010L1\u2013Selected Patients with NSCLC","author":"Herbst R. S.","year":"2020"},{"key":"e_1_2_11_80_1","first-page":"2020","volume-title":"Nivolumab plus Ipilimumab in Advanced Non\u2013Small\u2010Cell Lung Cancer","author":"Hellmann M. D.","year":"2019"},{"key":"e_1_2_11_81_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.8549"},{"key":"e_1_2_11_82_1","first-page":"1919","volume-title":"Durvalumab after Chemoradiotherapy in Stage III Non\u2013Small\u2010Cell Lung Cancer","author":"Antonia S. J.","year":"2017"},{"key":"e_1_2_11_83_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01308"},{"key":"e_1_2_11_84_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2007.13.9030"},{"key":"e_1_2_11_85_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(21)02098-5"},{"key":"e_1_2_11_86_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502931"},{"key":"e_1_2_11_87_1","first-page":"1672","volume-title":"Perioperative Durvalumab for Resectable Non\u2013Small\u2010Cell Lung Cancer","author":"Heymach J. V.","year":"2023"},{"key":"e_1_2_11_88_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2311926"},{"key":"e_1_2_11_89_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)01756-2"},{"key":"e_1_2_11_90_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2504966"},{"key":"e_1_2_11_91_1","first-page":"1824","volume-title":"Adjuvant Nivolumab versus Ipilimumab in Resected Stage III or IV Melanoma","author":"Weber J.","year":"2017"},{"key":"e_1_2_11_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2024.114327"},{"key":"e_1_2_11_93_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-21-1141"},{"key":"e_1_2_11_94_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-023-02583-2"},{"key":"e_1_2_11_95_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2025.115381"},{"key":"e_1_2_11_96_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(22)00562-1"},{"key":"e_1_2_11_97_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-018-0197-1"},{"key":"e_1_2_11_98_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211437"},{"key":"e_1_2_11_99_1","first-page":"1696","volume-title":"Neoadjuvant Nivolumab and Ipilimumab in Resectable Stage III Melanoma","author":"Blank C. U.","year":"2024"},{"key":"e_1_2_11_100_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2022.924542"},{"key":"e_1_2_11_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007637"},{"key":"e_1_2_11_102_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijpharm.2025.125755"},{"key":"e_1_2_11_103_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.immuni.2016.05.001"},{"key":"e_1_2_11_104_1","doi-asserted-by":"publisher","DOI":"10.1084\/jem.20100643"},{"key":"e_1_2_11_105_1","doi-asserted-by":"publisher","DOI":"10.1002\/eji.201344392"},{"key":"e_1_2_11_106_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0030676"},{"key":"e_1_2_11_107_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0081799"},{"key":"e_1_2_11_108_1","doi-asserted-by":"publisher","DOI":"10.18632\/oncotarget.15954"},{"key":"e_1_2_11_109_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0884"},{"key":"e_1_2_11_110_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-0806"},{"key":"e_1_2_11_111_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.it.2016.10.002"},{"key":"e_1_2_11_112_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-022-01281-5"},{"key":"e_1_2_11_113_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-CT051"},{"key":"e_1_2_11_114_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-007502"},{"key":"e_1_2_11_115_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-022-22975-7"},{"key":"e_1_2_11_116_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-024-61477-6"},{"key":"e_1_2_11_117_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-23-2455"},{"key":"e_1_2_11_118_1","doi-asserted-by":"publisher","DOI":"10.1038\/nrd.2018.75"},{"key":"e_1_2_11_119_1","doi-asserted-by":"publisher","DOI":"10.1158\/0008-5472.CAN-21-1109"},{"key":"e_1_2_11_120_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00620-7"},{"key":"e_1_2_11_121_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cllc.2022.11.004"},{"key":"e_1_2_11_122_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00242-5"},{"key":"e_1_2_11_123_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.molimm.2005.03.007"},{"key":"e_1_2_11_124_1","doi-asserted-by":"publisher","DOI":"10.1093\/annonc\/mdz112"},{"key":"e_1_2_11_125_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4"},{"key":"e_1_2_11_126_1","doi-asserted-by":"publisher","DOI":"10.1016\/S2352-3026(24)00186-8"},{"key":"e_1_2_11_127_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13020287"},{"key":"e_1_2_11_128_1","doi-asserted-by":"publisher","DOI":"10.1093\/oncolo\/oyag129"},{"key":"e_1_2_11_129_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)00521-4"},{"key":"e_1_2_11_130_1","first-page":"1196","volume-title":"Overall Survival Benefit with Tebentafusp in Metastatic Uveal Melanoma","author":"Nathan P.","year":"2021"},{"key":"e_1_2_11_131_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-022-02015-7"},{"key":"e_1_2_11_132_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2502099"},{"key":"e_1_2_11_133_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(25)00480-2"},{"key":"e_1_2_11_134_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-25-1211"},{"issue":"16","key":"e_1_2_11_135_1","article-title":"A Phase 2 Basket Trial of tarlatamab in Patients with Advanced DLL3\u2010expressing Tumors: University of California Lung Cancer Consortium UCCC\u201001\/UCLA L\u201010","volume":"43","author":"Oh M.","year":"2025","journal-title":"Journal of Clinical Oncology"},{"issue":"2","key":"e_1_2_11_136_1","first-page":"1325","article-title":"1325 Preclinical Activity and Safety Profile of JANX007, a Novel PSMA\u2010targeting Tumor\u2010Activated T Cell Engager for Treatment of Metastatic Castration\u2010Resistant Prostate Cancer","volume":"10","author":"DiRaimondo T.","year":"2022","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"e_1_2_11_137_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35738"},{"key":"e_1_2_11_138_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bbmt.2018.12.758"},{"key":"e_1_2_11_139_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2020.00885"},{"key":"e_1_2_11_140_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0413-z"},{"key":"e_1_2_11_141_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2021.09.013"},{"key":"e_1_2_11_142_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2022.939249"},{"key":"e_1_2_11_143_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-019-0432-4"},{"key":"e_1_2_11_144_1","first-page":"810","volume-title":"Pembrolizumab for Early Triple\u2010Negative Breast Cancer","author":"Schmid P.","year":"2020"},{"key":"e_1_2_11_145_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-009762"},{"key":"e_1_2_11_146_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ctrv.2022.102395"},{"key":"e_1_2_11_147_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0019"},{"key":"e_1_2_11_148_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-022-01894-4"},{"key":"e_1_2_11_149_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-025-58266-8"},{"key":"e_1_2_11_150_1","first-page":"875","volume-title":"Enfortumab Vedotin and Pembrolizumab in Untreated Advanced Urothelial Cancer","author":"Powles T.","year":"2024"},{"key":"e_1_2_11_151_1","first-page":"217","volume-title":"Pembrolizumab plus Chemotherapy in Advanced Triple\u2010Negative Breast Cancer","author":"Cortes J.","year":"2022"},{"key":"e_1_2_11_152_1","first-page":"1912","volume-title":"Sacituzumab Govitecan in Untreated, Advanced Triple\u2010Negative Breast Cancer","author":"Cort\u00e9s J.","year":"2025"},{"key":"e_1_2_11_153_1","doi-asserted-by":"publisher","DOI":"10.3389\/fphar.2022.972046"},{"key":"e_1_2_11_154_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.8611"},{"key":"e_1_2_11_155_1","doi-asserted-by":"publisher","DOI":"10.1021\/acsmedchemlett.5c00178"},{"key":"e_1_2_11_156_1","doi-asserted-by":"publisher","DOI":"10.1158\/1538-7445.AM2025-2138"},{"key":"e_1_2_11_157_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40257-025-00957-5"},{"key":"e_1_2_11_158_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005755"},{"key":"e_1_2_11_159_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00765"},{"key":"e_1_2_11_160_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.9505"},{"key":"e_1_2_11_161_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2014.58.9093"},{"key":"e_1_2_11_162_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40164-025-00711-x"},{"key":"e_1_2_11_163_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjonc-2024-000566"},{"key":"e_1_2_11_164_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2024.19462"},{"key":"e_1_2_11_165_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2501"},{"key":"e_1_2_11_166_1","first-page":"471716","volume-title":"Cell\u2010Based Therapies in GI Cancers: Current Landscape and Future Directions","author":"Nakayama I.","year":"2025"},{"key":"e_1_2_11_167_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03513-0"},{"key":"e_1_2_11_168_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2210859"},{"key":"e_1_2_11_169_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2025.43.16_suppl.4508"},{"key":"e_1_2_11_170_1","first-page":"473440","volume-title":"Autologous T\u2010Cell Therapies in Solid Tumor Malignancies: Current Landscape and Future Opportunities","author":"Reinhorn D.","year":"2025"},{"key":"e_1_2_11_171_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(24)00319-2"},{"issue":"2","key":"e_1_2_11_172_1","first-page":"0687","article-title":"687 ACTengine IMA203 TCR\u2010T Targeting PRAME Shows Deep and Durable Anti\u2010Tumor Activity in Heavily Pretreated Solid Cancer Patients","volume":"12","author":"Wermke M.","year":"2024","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"e_1_2_11_173_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.2500"},{"key":"e_1_2_11_174_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-020-01225-1"},{"key":"e_1_2_11_175_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS8650"},{"key":"e_1_2_11_176_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.TPS2677"},{"key":"e_1_2_11_177_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12091316"},{"key":"e_1_2_11_178_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2024-011119"},{"key":"e_1_2_11_179_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2005-06-2399"},{"key":"e_1_2_11_180_1","doi-asserted-by":"publisher","DOI":"10.1172\/JCI46266"},{"key":"e_1_2_11_181_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1433989"},{"key":"e_1_2_11_182_1","doi-asserted-by":"publisher","DOI":"10.1080\/2162402X.2025.2452654"},{"key":"e_1_2_11_183_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41577-022-00680-w"},{"key":"e_1_2_11_184_1","doi-asserted-by":"publisher","DOI":"10.1158\/2159-8290.CD-23-1266"},{"key":"e_1_2_11_185_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02305-x"},{"key":"e_1_2_11_186_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-1160"},{"key":"e_1_2_11_187_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.pharmthera.2022.108189"},{"key":"e_1_2_11_188_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.575597"},{"key":"e_1_2_11_189_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-020-2422-6"},{"key":"e_1_2_11_190_1","doi-asserted-by":"publisher","DOI":"10.1172\/jci.insight.184545"},{"key":"e_1_2_11_191_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12032-024-02404-7"},{"key":"e_1_2_11_192_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2007-05-089375"},{"key":"e_1_2_11_193_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2011.40.0655"},{"key":"e_1_2_11_194_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-021-21241-0"},{"key":"e_1_2_11_195_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2024.1369743"},{"key":"e_1_2_11_196_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(22)00372-2"},{"key":"e_1_2_11_197_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(23)02268-7"},{"key":"e_1_2_11_198_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.17_suppl.LBA9512"},{"key":"e_1_2_11_199_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-023-06063-y"},{"key":"e_1_2_11_200_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-024-08507-5"},{"key":"e_1_2_11_201_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41586-025-10004-2"},{"key":"e_1_2_11_202_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.semcancer.2022.12.003"},{"key":"e_1_2_11_203_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ymthe.2020.09.038"},{"key":"e_1_2_11_204_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01247-x"},{"key":"e_1_2_11_205_1","doi-asserted-by":"publisher","DOI":"10.1038\/s43018-022-00418-6"},{"key":"e_1_2_11_206_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-025-03876-4"},{"key":"e_1_2_11_207_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1001294"},{"key":"e_1_2_11_208_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2023.07.006"},{"key":"e_1_2_11_209_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers14112756"},{"key":"e_1_2_11_210_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41591-021-01544-x"},{"key":"e_1_2_11_211_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2023-006755"},{"key":"e_1_2_11_212_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0623-z"},{"key":"e_1_2_11_213_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000398"},{"key":"e_1_2_11_214_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005921"},{"key":"e_1_2_11_215_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005920"},{"key":"e_1_2_11_216_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-005923"},{"issue":"7","key":"e_1_2_11_217_1","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2023-007309","article-title":"Society for Immunotherapy of Cancer (SITC) Checkpoint Inhibitor Resistance Definitions: Efforts to Harmonize Terminology and Accelerate Immuno\u2010Oncology Drug Development","volume":"11","author":"Kluger H. M.","year":"2023","journal-title":"Journal for ImmunoTherapy of Cancer"},{"key":"e_1_2_11_218_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2017.01.017"},{"key":"e_1_2_11_219_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00097-8"},{"key":"e_1_2_11_220_1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0672-3"},{"key":"e_1_2_11_221_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(20)30328-4"},{"key":"e_1_2_11_222_1","doi-asserted-by":"publisher","DOI":"10.1007\/s40259-024-00700-2"},{"key":"e_1_2_11_223_1","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1688699"},{"key":"e_1_2_11_224_1","doi-asserted-by":"publisher","DOI":"10.3389\/fonc.2024.1489977"},{"key":"e_1_2_11_225_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.34716"},{"key":"e_1_2_11_226_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2022-004771"},{"key":"e_1_2_11_227_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41571-020-0399-6"},{"key":"e_1_2_11_228_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2017.75.6270"},{"key":"e_1_2_11_229_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-23-3643"},{"key":"e_1_2_11_230_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12943-025-02477-6"},{"key":"e_1_2_11_231_1","doi-asserted-by":"publisher","DOI":"10.1002\/cac2.12546"},{"key":"e_1_2_11_232_1","doi-asserted-by":"publisher","DOI":"10.3390\/cells12131787"},{"key":"e_1_2_11_233_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12951-021-00846-z"},{"key":"e_1_2_11_234_1","doi-asserted-by":"publisher","DOI":"10.1002\/cncr.35250"},{"key":"e_1_2_11_235_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15164125"},{"key":"e_1_2_11_236_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ejca.2019.07.001"},{"key":"e_1_2_11_237_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41416-025-03021-5"},{"key":"e_1_2_11_238_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2312695"},{"key":"e_1_2_11_239_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.23.00280"},{"key":"e_1_2_11_240_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2024.55630"},{"key":"e_1_2_11_241_1","doi-asserted-by":"publisher","DOI":"10.1136\/jitc-2019-000391"}],"container-title":["Advanced Science"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/advs.76020","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/full-xml\/10.1002\/advs.76020","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/advs.76020","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T17:08:55Z","timestamp":1784048935000},"score":1,"resource":{"primary":{"URL":"https:\/\/advanced.onlinelibrary.wiley.com\/doi\/10.1002\/advs.76020"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":240,"journal-issue":{"issue":"35","published-print":{"date-parts":[[2026,6]]}},"alternative-id":["10.1002\/advs.76020"],"URL":"https:\/\/doi.org\/10.1002\/advs.76020","archive":["Portico"],"relation":{},"ISSN":["2198-3844","2198-3844"],"issn-type":[{"value":"2198-3844","type":"print"},{"value":"2198-3844","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"2026-01-29","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-05-27","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-06-09","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}],"article-number":"e76020"}}